phenyltoxamine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Phenyltoloxamine is an ethanolamine derivative with antihistaminic property, which is used in combination with some analgesics for the temporary relief of minor aches and pains associated with headache; backache; muscular aches; temporarily reduces fever and some others disorders. Phenyltoloxamine blocks H1 histamine receptor, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP levels, thereby inhibiting smooth muscle constriction of various tissues, decreasing capillary permeability and decreasing other histamine-activated allergic reactions.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

n,n-dimethyl-2-(alpha-phenyl-o-tolyloxy)ethylamine | phenoxadrin | phenoxadrine | phentoloxamine | phenyltoloxamine | phenyltoloxamine citrate | phenyltoloxamine dihydrogen citrate | phenyltoloxamine hcl | phenyltoloxamine hydrochloride | phenyltoxamine

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Hypersensitivity (approved 1952)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Arthritis (Phase 3)

Fever ()

Headache ()

Pain ()

Stomach Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue